As one of the 25 million rare disease patients in the United States, I was pleased to see President Obama stress the need for continued medical innovation when he a
With nearly 5,000 medicines in the pipeline, it's obvious America's biopharmaceutical sector is on the cusp of life-saving breakthroughs every day.
Tomorrow, in London, John Castellani, PhRMA President & CEO, will give the closing address to the Economist's PhRMA Summit 2013 . His remarks will focus on the future of the biopharmaceutical research industry, the value of medicines to patient health and the economy and what kinds of policies are needed to foster investment and biopharmaceutical innovation.
Rare disease is defined as one that strikes fewer than 200,000 patients in the U.S. According to the National Human Genome Research Institute, there are 25 to 30 million patients in the U.S.
Depression. I think it is pretty safe to assume that you know someone who suffers from it.
On Monday, I posted a great chart from Forbes demonstrating how vaccines have improved health. No diphtheria, no polio, no small pox in the U.S. today. ZERO.
Beginning March 4, Singapore will host the 16th round of negotiations for the Trans-Pacific Partnership (TPP) agreement, and tomorrow, Jay Taylor, PhRMA Vice President of International Affairs, will join Ambassador Joh
Vaccines work. Here's a great graphic that shows how vaccines have helped reduce the U.S. incidence of some of the awful killer diseases of history.
The New York Times this morning unveiled a few details about a new Obama initiative that could help further medical research for neurological diseases.
Yesterday on The Hill's Congress Blog, our President and CEO John J.
02.15.13 | By Christian Clymer
Aside from the acai-blueberry-broccoli-pomegranate-pineapple-kiwi-strawberry flavoring you put in your glass of water every day, are you curious about what else is in it? Lots of folks are, and there's been quite a bit of online "discussion" about a new study on the effects of pharmaceutical products in the water supply.